首页 › 基金 › GILEAD SCIENCES, INC. › KYTX
GILEAD SCIENCES, INC. 对 KYTX 的持仓历史
Kyverna Therapeutics Inc. · 医疗保健
GILEAD SCIENCES, INC. 在 Q3 2026 的 13F 申报中披露持有 KYTX(Kyverna Therapeutics Inc.)4,126,119 股,市值约 US$28.1M,约占其申报组合的 1.92%,在其申报持仓中市值排名第 4 位。 GILEAD SCIENCES, INC. 最近 8 个申报季度中有 8 个季度披露了 KYTX 持仓,最早可追溯至 Q4 2024。
最后更新: 2026-11-06 · 来源: SEC EDGAR Form 13F-HR
GILEAD SCIENCES, INC. 对 KYTX 的持仓演变
GILEAD SCIENCES, INC. 于 Q4 2024 首次披露 KYTX 持仓:4,126,119 股(约 US$15.4M)。 该持仓在 Q4 2025 达到峰值 4,126,119 股,市值约 US$38.8M。 在 8 次申报中,GILEAD SCIENCES, INC. 的持股数量始终未变。 最近一期申报(Q3 2026)显示持股 4,126,119 股、市值约 US$28.1M。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q4 2024 | 4.13M | $15.43M | 新进 |
| Q1 2025 | 4.13M | $7.96M | 持有 |
| Q2 2025 | 4.13M | $12.67M | 持有 |
| Q3 2025 | 4.13M | $24.76M | 持有 |
| Q4 2025 | 4.13M | $38.79M | 持有 |
| Q1 2026 | 4.13M | $35.61M | 持有 |
| Q2 2026 | 4.13M | $36.76M | 持有 |
| Q3 2026 | 4.13M | $28.06M | 持有 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 KYTX 与 13F 数据
KYTX(Kyverna Therapeutics Inc.)属于医疗保健行业。我们追踪的基金中还有 47 只申报持有 KYTX,申报仓位最大的包括:GordonMD Global Investments LP (US$37.8M), Bain Capital Life Sciences Investors, LLC (US$25.7M), AIGH Capital Management LLC (US$24.9M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 KYTX 的基金
- GordonMD Global Investments LP 4.24M 股 · $37.82M · Q2 2026
- Bain Capital Life Sciences Investors, LLC 2.88M 股 · $25.71M · Q2 2026
- AIGH Capital Management LLC 2.80M 股 · $24.91M · Q2 2026
- Insight Holdings Group, LLC 989.05K 股 · $8.81M · Q2 2026
- Propel Bio Management, LLC 883.20K 股 · $7.87M · Q2 2026
- MBB PUBLIC MARKETS I LLC 614.48K 股 · $5.47M · Q2 2026
更多关于 GILEAD SCIENCES, INC.
常见问题
How long has GILEAD SCIENCES, INC. held KYTX?
GILEAD SCIENCES, INC. has disclosed KYTX holdings in 8 of the last 8 reported quarters, going back to Q4 2024.
What is GILEAD SCIENCES, INC.'s current position in KYTX?
As of Q3 2026, GILEAD SCIENCES, INC. holds 4.13M shares of KYTX (Kyverna Therapeutics Inc.), valued at $28.06M, representing 1.92% of its reported portfolio and ranking #4.
Has GILEAD SCIENCES, INC. been buying or selling KYTX?
In the latest 13F filing (Q3 2026), GILEAD SCIENCES, INC. held unchanged its position in KYTX. The position peaked in Q4 2025 at 4.13M shares.
Which other funds hold KYTX?
Other major institutional holders of KYTX include GordonMD Global Investments LP, Bain Capital Life Sciences Investors, LLC, AIGH Capital Management LLC, among 47 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.